Verrica Pharmaceuticals Inc. Sale of Stock, Consideration Received on Transaction
Verrica Pharmaceuticals Inc. (VRCA) reported Sale of Stock, Consideration Received on Transaction of $49.10 million for the 1-month period ending 2025-11-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2026-08-06
- 2025-11-30: Sale of Stock, Consideration Received on Transaction 1 month $49.10M.
- 2025-11-23: Sale of Stock, Consideration Received on Transaction $49.10M.
- 2024-11-22: Sale of Stock, Consideration Received on Transaction $39.60K.
| Period end | Sale of Stock, Consideration Received on Transaction | Sale of Stock, Consideration Received on Transaction 1 month |
|---|---|---|
| 2025-11-30 | $49.10M 10-Q · filed 2026-08-06 | |
| 2025-11-23 | $49.10M 10-K · filed 2026-03-11 | |
| 2024-11-22 | $39.60K 10-Q · filed 2025-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |